Dermata Therapeutics (DRMA) Stock Price, News & Analysis

Company Overview

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques. This integrated platform enables the identification and optimization of both topical and oral small molecules that modulate key intracellular signaling pathways involved in skin inflammation.

Headquartered in Cambridge, Massachusetts, Dermata collaborates with academic institutions and contract research organizations across the United States and Europe to conduct translational studies and clinical trials. The company’s network of clinical sites supports the efficient advancement of its pipeline from preclinical research through clinical development.

Dermata’s management team brings together expertise in pharmaceutical research and development, regulatory affairs and dermatology commercialization. With a focus on addressing unmet needs in skin health, the company aims to deliver best-in-class therapies that improve outcomes and quality of life for patients living with inflammatory skin diseases.

Key Stats

• Today's Range: $5.54 to $6.22
• 50-Day Range: $5.19 to $7.30
• 52-Week Range: $5.04 to $23.80
• Volume: 137,684 shs
• Average Volume: 71,270 shs
• Market Capitalization: $4.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Dermata Therapeutics Stock Analysis - MarketRank™

Dermata Therapeutics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Dermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Dermata Therapeutics has a consensus price target of $10.00, representing about 67.5% upside from its current price of $5.97.

Amount of Analyst Coverage

Dermata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dermata Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dermata Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dermata Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.90% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dermata Therapeutics does not currently pay a dividend.

Dividend Growth

Dermata Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.90% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.96

News Sentiment

Dermata Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Dermata Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for DRMA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

1 people have added Dermata Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.50% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.67% of the stock of Dermata Therapeutics is held by institutions.

DRMA Stock Analysis - Frequently Asked Questions

How have DRMA shares performed this year?

Dermata Therapeutics' stock was trading at $13.50 on January 1st, 2025. Since then, DRMA shares have decreased by 55.8% and is now trading at $5.9710.

How were Dermata Therapeutics' earnings last quarter?

Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($1.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.90) by $1.24.

When did Dermata Therapeutics' stock split?

Shares of Dermata Therapeutics reverse split on the morning of Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Dermata Therapeutics IPO?

Dermata Therapeutics (DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00 per share.

Who are Dermata Therapeutics' major shareholders?

Dermata Therapeutics' top institutional investors include Armistice Capital LLC (50.50%).

How do I buy shares of Dermata Therapeutics?

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dermata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRMA
• CIK: 1853816
• Web: www.dermatarx.com
• Phone: 858-800-2543
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dermata Therapeutics: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +67.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -214.98%
• Return on Assets: -153.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.47
• Quick Ratio: 6.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.20 per share
• Price / Book: 0.96

Miscellaneous

• Outstanding Shares: 680,000
• Free Float: 556,000
• Market Cap: $4.06 million
• Optionable: Not Optionable
• Beta: 0.56